US20210106552A1 - Methods for treating triple negative breast cancer using salvianolic acid b - Google Patents
Methods for treating triple negative breast cancer using salvianolic acid b Download PDFInfo
- Publication number
- US20210106552A1 US20210106552A1 US17/046,577 US201917046577A US2021106552A1 US 20210106552 A1 US20210106552 A1 US 20210106552A1 US 201917046577 A US201917046577 A US 201917046577A US 2021106552 A1 US2021106552 A1 US 2021106552A1
- Authority
- US
- United States
- Prior art keywords
- salt
- sal
- subject
- salvianolic acid
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- SNKFFCBZYFGCQN-VWUOOIFGSA-N Lithospermic acid B Natural products C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2[C@H](C(=O)O[C@H](CC=3C=C(O)C(O)=CC=3)C(O)=O)[C@H](OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-VWUOOIFGSA-N 0.000 title claims abstract description 136
- STCJJTBMWHMRCD-UHFFFAOYSA-N salvianolic acid B Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=O)C=Cc2cc(O)c(O)c3OC(C(C(=O)OC(Cc4ccc(O)c(O)c4)C(=O)O)c23)c5ccc(O)c(O)c5 STCJJTBMWHMRCD-UHFFFAOYSA-N 0.000 title claims abstract description 135
- SNKFFCBZYFGCQN-UHFFFAOYSA-N 2-[3-[3-[1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid Chemical compound C=1C=C(O)C=2OC(C=3C=C(O)C(O)=CC=3)C(C(=O)OC(CC=3C=C(O)C(O)=CC=3)C(O)=O)C=2C=1C=CC(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-UHFFFAOYSA-N 0.000 title claims abstract description 133
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 title claims abstract description 38
- 208000022679 triple-negative breast carcinoma Diseases 0.000 title claims abstract description 38
- 238000000034 method Methods 0.000 title claims abstract description 35
- 229940106189 ceramide Drugs 0.000 claims abstract description 49
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims abstract description 40
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims abstract description 40
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims abstract description 40
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims abstract description 40
- 102000044956 Ceramide glucosyltransferases Human genes 0.000 claims abstract description 27
- 108091000114 ceramide glucosyltransferase Proteins 0.000 claims abstract description 27
- 230000006907 apoptotic process Effects 0.000 claims abstract description 23
- 150000003839 salts Chemical class 0.000 claims abstract description 22
- 102100030928 Lactosylceramide alpha-2,3-sialyltransferase Human genes 0.000 claims abstract description 20
- 108010076477 haematoside synthetase Proteins 0.000 claims abstract description 20
- 230000001404 mediated effect Effects 0.000 claims abstract description 20
- 230000003247 decreasing effect Effects 0.000 claims abstract description 19
- 239000003814 drug Substances 0.000 claims abstract description 18
- 239000012453 solvate Substances 0.000 claims abstract description 10
- 241000124008 Mammalia Species 0.000 claims abstract description 4
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 90
- 206010028980 Neoplasm Diseases 0.000 claims description 69
- 229960004679 doxorubicin Drugs 0.000 claims description 44
- 201000011510 cancer Diseases 0.000 claims description 40
- 230000001939 inductive effect Effects 0.000 claims description 8
- 238000011374 additional therapy Methods 0.000 claims description 7
- 238000007918 intramuscular administration Methods 0.000 claims description 7
- 238000007912 intraperitoneal administration Methods 0.000 claims description 7
- 238000007913 intrathecal administration Methods 0.000 claims description 7
- 238000001990 intravenous administration Methods 0.000 claims description 7
- 159000000003 magnesium salts Chemical class 0.000 claims description 7
- 239000007921 spray Substances 0.000 claims description 7
- 238000007920 subcutaneous administration Methods 0.000 claims description 7
- 230000000699 topical effect Effects 0.000 claims description 7
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical group [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims description 6
- 159000000007 calcium salts Chemical class 0.000 claims description 6
- 150000002505 iron Chemical class 0.000 claims description 6
- 150000002696 manganese Chemical class 0.000 claims description 6
- 239000002246 antineoplastic agent Substances 0.000 claims description 5
- 229940127089 cytotoxic agent Drugs 0.000 claims description 5
- 238000009169 immunotherapy Methods 0.000 claims description 4
- 238000001356 surgical procedure Methods 0.000 claims description 4
- 238000010317 ablation therapy Methods 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 238000001959 radiotherapy Methods 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 description 121
- 230000014509 gene expression Effects 0.000 description 54
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 238000011282 treatment Methods 0.000 description 18
- 206010006187 Breast cancer Diseases 0.000 description 16
- 208000026310 Breast neoplasm Diseases 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 14
- 230000003833 cell viability Effects 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 230000002401 inhibitory effect Effects 0.000 description 13
- 102100038595 Estrogen receptor Human genes 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 238000001262 western blot Methods 0.000 description 12
- 108010060385 Cyclin B1 Proteins 0.000 description 11
- 102100032340 G2/mitotic-specific cyclin-B1 Human genes 0.000 description 11
- 108010068192 Cyclin A Proteins 0.000 description 10
- 102100025191 Cyclin-A2 Human genes 0.000 description 10
- 102000007469 Actins Human genes 0.000 description 9
- 108010085238 Actins Proteins 0.000 description 9
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 description 9
- 101710196141 Estrogen receptor Proteins 0.000 description 9
- 102000000763 Survivin Human genes 0.000 description 9
- 108010002687 Survivin Proteins 0.000 description 9
- 238000013459 approach Methods 0.000 description 9
- 230000022131 cell cycle Effects 0.000 description 9
- 238000009825 accumulation Methods 0.000 description 8
- 230000005757 colony formation Effects 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000000684 flow cytometry Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 108050006400 Cyclin Proteins 0.000 description 7
- 150000001783 ceramides Chemical class 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 102100036691 Proliferating cell nuclear antigen Human genes 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 108090000397 Caspase 3 Proteins 0.000 description 5
- 102100029855 Caspase-3 Human genes 0.000 description 5
- 102000004091 Caspase-8 Human genes 0.000 description 5
- 108090000538 Caspase-8 Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000043136 MAP kinase family Human genes 0.000 description 5
- 108091054455 MAP kinase family Proteins 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 230000001640 apoptogenic effect Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 206010059866 Drug resistance Diseases 0.000 description 4
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 238000010293 colony formation assay Methods 0.000 description 4
- 150000002305 glucosylceramides Chemical class 0.000 description 4
- 230000013595 glycosylation Effects 0.000 description 4
- 238000006206 glycosylation reaction Methods 0.000 description 4
- 238000002991 immunohistochemical analysis Methods 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 108010007005 Estrogen Receptor alpha Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 3
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 3
- -1 Sal-B magnesium salt Chemical class 0.000 description 3
- 241000304195 Salvia miltiorrhiza Species 0.000 description 3
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000003021 clonogenic effect Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108090000331 Firefly luciferases Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101000911513 Homo sapiens Uncharacterized protein FAM215A Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 102100026728 Uncharacterized protein FAM215A Human genes 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003388 anti-hormonal effect Effects 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 238000011717 athymic nude mouse Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000018486 cell cycle phase Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 108091008039 hormone receptors Proteins 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 102000003998 progesterone receptors Human genes 0.000 description 2
- 108090000468 progesterone receptors Proteins 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000004565 tumor cell growth Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 1
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- 238000010159 Duncan test Methods 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 1
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 101000882584 Homo sapiens Estrogen receptor Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- 230000037364 MAPK/ERK pathway Effects 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 238000012288 TUNEL assay Methods 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 241000021375 Xenogenes Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- WPIHMWBQRSAMDE-YCZTVTEBSA-N beta-D-galactosyl-(1->4)-beta-D-galactosyl-N-(pentacosanoyl)sphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO[C@@H]1O[C@H](CO)[C@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O)[C@H](O)\C=C\CCCCCCCCCCCCC WPIHMWBQRSAMDE-YCZTVTEBSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 102000011941 human estrogen receptor alpha Human genes 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000000683 nonmetastatic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000012634 optical imaging Methods 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 239000003790 pyrimidine antagonist Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000004137 sphingolipid metabolism Effects 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/86—Benzo [b] furans; Hydrogenated benzo [b] furans with an oxygen atom directly attached in position 7
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- This application relates to the treatment of cancer by administering salvianolic acid B, and in particular to the treatment of triple-negative breast cancer.
- Breast cancer is the most common cancer in women and the second highest lethal form of cancer in the United States. Studies have shown that the incidence of breast cancer has been gradually decreasing in the last two decades; however, women in the United States have a one in eight chance of developing breast cancer in their lifetimes.
- TNBC triple-negative breast cancer
- ER- ⁇ estrogen receptor ⁇
- HER2 human epidermal growth factor receptor-2
- doxorubicin doxorubicin
- Salvianolic acid B (Sal-B) is a natural compound extracted from Salvia miltiorrhiza Bunge, a well-known Chinese herbal medicine for preventing and treating vascular diseases.
- Sal-B has surprisingly been found to have a high potency against triple negative breast cancer (TNBC), which is mediated at least in part by inhibiting tumor cell growth and enhancing ceramide-mediated apoptosis through GCS-catalyzed ceramide glycosylation.
- TNBC triple negative breast cancer
- a method of treating breast cancer in a subject in need thereof comprises administering a therapeutically effective amount of Sal-B to the subject.
- the breast cancer is TNBC.
- a method for treating cancer in a subject includes inducing ceramide-mediated apoptosis of cancer cells by decreasing the level of one or more of glucosylceramide synthase and GM3 synthase in the subject through the use of an effective amount of Sal-B.
- the cancer is TNBC.
- a method of inducing ceramide-mediated apoptosis by decreasing the level of one or more of glucosylceramide synthase and GM3 synthase in cancer cells of a subject comprises administering to said subject an effective amount of Sal-B.
- Sal-B may be administered by any suitable route, including any of intravenous, oral, parenteral, intraperitoneal, intramuscular, intrathecal, subcutaneous, transdermal, vaginal, rectal, sublingual, buccal, nasal, topical, or inhalation spray.
- the Sal-B is administered once a day.
- the Sal-B may be administered at a dose of about 0.1 ⁇ g to about 500 mg/kg.
- Sal-B may be provided in the form of a pharmaceutically acceptable salt or solvate.
- the pharmaceutically acceptable salt may be an aluminum salt, calcium salt, iron salt, magnesium salt, manganese salt, or combination thereof.
- the method further includes administering at least one additional therapy to the subject.
- the at least one additional therapy may comprise one or more of radiotherapy, surgery, chemotherapeutic agent, hormone ablation therapy, pro-apoptosis therapy, and immunotherapy.
- the chemotherapeutic agent may comprise doxorubicin.
- Sal-B or a pharmaceutically acceptable salt or solvate thereof is provided for use in the manufacture of a medicament for treating triple negative breast cancer is provided.
- Sal-B or a pharmaceutically acceptable salt or solvate thereof is provided for use as a medicament for treating triple negative breast cancer.
- the medicament may be formulated for administration by at least one of intravenous, oral, parenteral, intraperitoneal, intramuscular, intrathecal, subcutaneous, transdermal, vaginal, rectal, sublingual, buccal, nasal, topical, or inhalation spray administration.
- the Sal-B is formulated at a dose of about 0.1 ⁇ g to about 500 mg/kg.
- the pharmaceutically acceptable salt is an aluminum salt, calcium salt, iron salt, magnesium salt, manganese salt, or a combination thereof.
- the subject may be a mammal, and preferably is a human.
- FIG. 1 includes luciferase-based bioluminescent images and graphs showing the relative survival percentage of MDA-MB-231 (“MDA”) and MCF-7 cells after exposure to various concentrations of Sal-B and doxorubicin. Inhibitory effects of Sal-B on the cell viability and colony formation of both triple-negative MDA cells and hormone-receptor positive MCF-7 breast cancer cells are demonstrated.
- the cell viability was analyzed by luciferase-based bioluminescent imaging after exposure to Sal-B (50 ⁇ M, 100 ⁇ M, 150 ⁇ M and 200 ⁇ M) (panel A) and doxorubicin (0.1 ⁇ M, 0.2 ⁇ M, 0.5 ⁇ M and 1 ⁇ M) (panel B) for 24 hours, respectively.
- FIG. 2 includes photographs and bar graphs showing the colony formation ability of MDA and MCF-7 cells after exposure to various concentrations of Sal-B and doxorubicin.
- the colony formation of MDA cells was determined with colony formation assay after exposure to various doses of Sal-B (1 ⁇ M, 10 ⁇ M, 25 ⁇ M, 50 ⁇ M and 100 ⁇ M) for 24 h and colonies were allowed to grow for 10 days.
- a colony containing more than 50 cells was considered to represent a viable clonogenic cell.
- the results represent the mean ⁇ SD. There were significant differences for the colony formation capability between untreated and Sal-B treated cells (P ⁇ 0.05).
- FIG. 3 includes flow cytometry plots and bar graphs showing the effects of Sal-B on cell cycle and cell cycle related protein expression in MCF-7 and MDA cells.
- Panels A and B show the DNA content profiles of MCF-7 and MDA cells, respectively, by flow cytometry.
- the percentages of cells in the different phases of cell cycle are summarized as mean ⁇ SD (panel C). No significant change was observed in the cell cycle phases of either MDA or MCF-7 cells after Sal-B treatment.
- FIG. 4 includes Western blot results for the expression of cell cycle related protein cyclin A and cyclin B1.
- the expression of cyclin A and cyclin B1 was normalized by the expression of the internal control ⁇ -actin.
- the cells were treated with 50 ⁇ M and 100 ⁇ M Sal-B, respectively, for 24 hours.
- Doxorubicin (0.1 ⁇ M and 1 ⁇ M) was used as a control.
- For the cyclin A and cyclin B1 expression down-regulation of cyclin B1 but not cyclin A expression was found in both Sal-B treated MDA and MCF-7 cells. Treatment with 1 ⁇ M doxorubicin resulted in reduction of both cyclin A and cyclin B1 expression in both cell lines.
- FIG. 5 is a bar graph showing the inhibitory effects of Sal-B on the growth of triple-negative MDA tumor xenografts in nude mice.
- the mice were treated with either Sal-B (80 mg/kg three times per week) or doxorubicin (4 mg/kg every 4 weeks) and all mice were sacrificed on day 37.
- the bar graph shows the tumor weights on day 37.
- the results represent the mean ⁇ SD and *P ⁇ 0.05 means significant difference with respect to control mice.
- FIG. 6 includes immunohistochemical analysis for proliferating cell nuclear antigen (PCNA) levels in Sal-B treated and doxorubicin treated tumors.
- PCNA proliferating cell nuclear antigen
- FIG. 7 includes Western blot and immunohistochemical analysis demonstrating the effects of Sal-B on the apoptosis in both MCF-7 and MDA cancer cells and tumor xenografts.
- Western blot analysis was used to determine the expression of apoptosis-related proteins Bcl-xL, survivin, caspase-3 and caspase-8.
- ⁇ -actin was used as an internal control.
- the cells were treated with Sal-B (50 ⁇ M and 100 ⁇ M) and doxorubicin (0.1 ⁇ M and 1 ⁇ M), respectively, for 24 hours.
- Both Sal-B and doxorubicin downregulated both Bcl-xL and survivin protein expression, but not the protein levels of caspase-3 and caspase-8 in the MDA and MCF-7 cell lines.
- Immunohistochemical analysis was used to detect the expressions of Bcl-xL (panel B) and survivin (panel C) in MDA tumor xenografts, showing decreased expression of Bcl-xL and survivin in the Sal-B and doxorubicin treated tumors than in the untreated tumors (P ⁇ 0.05).
- Apoptotic cells in MDA tumor xenografts were analyzed by a TUNEL assay, showing an increase in apoptotic cells in the Sal-B and doxorubicin treated xenografts than in the untreated tumors (P ⁇ 0.05) (panel D).
- FIG. 8 includes Western blot results and bar graphs showing the expression of glucosylceramide synthase (GCS) and GM3 synthase in MDA and MCF-7 cells treated by various concentrations of Sal-B (panel A). The amount of protein expression was normalized by the expression of the internal control ⁇ -actin (panels B and C). Results demonstrated that Sal-B enhances ceramide accumulation and decreases the expression of GCS and GM3 enzymes.
- GCS glucosylceramide synthase
- GM3 synthase GM3 synthase
- FIG. 9 includes a flow cytometry plot (panel A), bar graph (panel B), and immunohistochemistry images (panel C).
- MDA cells were treated with 50 ⁇ M and 100 ⁇ M of Sal-B, respectively, for 24 h and ceramide levels were then analyzed by flow cytometry (A).
- Immunohistochemistry was used to evaluate the expression of ceramides in MDA tumor xenografts (C) and the ceramide positive cells were counted (B).
- FIG. 10 includes Western blot images and bar graphs showing the effects of Sal-B on the ER- ⁇ and p-ERK expression in cancer cells.
- Panel A shows the ER- ⁇ expression in MCF-7 cells treated with Sal-B and doxorubicin and panel B shows the expression of p-ERK in MCF-7 and MDA cells following exposure to different concentrations of Sal-B for 24 hours. The amount of protein was normalized by that of the internal control ⁇ -actin.
- Salvianolic acid B (Sal-B) is a natural compound extracted from Salvia miltiorrhiza Bunge, a well-known Chinese herbal medicine for preventing and treating vascular diseases.
- Sal-B has the following structure:
- TNBC triple-negative breast cancer
- the cancer may be treated by inducing ceramide-mediated apoptosis in cancer cells by administering a therapeutically effective amount of Sal-B.
- the cancer is treated by enhancing, ceramide-mediated apoptosis by decreasing expression of glucosylceramide synthase and/or GM3 synthase.
- early inhibition of GCS has potential to prevent drug resistance.
- the cancer being treated is one in, which ceramide-mediated apoptosis can be induced via the decrease in expression of one or more of glucosylceramide and GM3 synthase.
- the cancer being treated is breast cancer, and in a more particular aspect, the cancer being treated is triple-negative breast cancer (TNBC).
- Sal-B has a suppressing effect against head and, neck squamous carcinoma cells via dose-dependent inhibition of prostaglandin E 2 synthesis and inhibition of COX-2 expression
- Sal-B was effective to increase ceramide accumulation and inhibit anti-apoptotic protein expression in TNBC cells.
- the ceramide accumulation was accompanied by decreased expression of glucosylceramide and GM3 synthases, which are two key enzymes regulating ceramide metabolism.
- Sal-B exerts its antitumor effects at least partially by inducing the ceramide accumulation and ceramide-mediated apoptosis via inhibiting the expression of glucosylceramide and GM3 synthases, which was independent of estrogen receptor ⁇ .
- the term “subject” refers to a mammalian subject, in one particular aspect a human subject, in need of a treatment.
- the subject may be any one of a subject having been diagnosed with a cancer (such as TNBC), a subject undergoing treatment for any disorder including a cancer (such as TNBC), an asymptomatic subject having undergone a test or scan indicative of an underlying condition, a symptomatic subject having undergone a test or scan indicative of an underlying condition, a subject undergoing clinical treatment including cancer therapy or clinical intervention in the form of drugs, chemotherapy, immunotherapy, surgery, radiation or therapeutic devices, or not yet undergoing any clinical treatment.
- treatment refers to an intervention performed to alter the pathology of, or carrying out a procedure, to obtain a desired pharmacologic and/or physiologic effect.
- the effect may be therapeutic in terms of effecting a partial or complete cure for a disease, condition, symptom, and/or adverse effect attributable to the disease or condition.
- These terms also cover any treatment of a condition or disease in the subject, and include: (a) inhibiting the disease, i.e., arresting its development; (b) causing regression of the disease; (c) reducing the severity of a symptom of the disease; and/or (d) reducing the frequency of a symptom of the disease or condition.
- cancer and “cancerous” refer to or describe the physiological condition in mammals that is typically characterized in part by unregulated cell growth.
- cancer refers to non-metastatic and metastatic cancers, including early stage and late stage cancers.
- the cancer being treated herein is one in which ceramide-mediated apoptosis can be induced via the decrease in expression of at least one of glucosylceramide synthase and GM3 synthase.
- the cancer is breast cancer.
- the cancer is TNBC.
- a therapeutically effective amount may be an amount sufficient to provide an observable therapeutic benefit.
- the terms “therapeutically effective amount” or “effective amount” refer to the amount of Sal-B and/or other active ingredient required to confer a biological or meaningful benefit to the subject, such as a biological or medical response or improvement sought by a medical doctor or other medical professional.
- the terms “therapeutically effective amount” or “effective amount” are intended to mean the amount of Sal-B and/or other active ingredient that will bring about a biologically meaningful improvement in a subject's symptom or prognosis. Doses that exhibit large therapeutic indices are preferred. Effective amounts may vary, as recognized by those skilled in the art, depending, for example, on route of administration, dosage form, inclusion of additional active agents, as well as age, weight, sensitivity, and health of the subject.
- the Sal-B may be in the form of a pharmaceutically acceptance salt or solvate.
- a pharmaceutically acceptable salt may be any salt which retains the activity of the parent compound and does not impart any unduly undesirable effects on a subject to whom it is administered and in the context in which it is administered.
- Pharmaceutically acceptable salts may include, but are not limited to, metal salts such as aluminum, calcium, iron, magnesium, manganese, and complex salts.
- a method for inducing ceramide-mediated apoptosis by decreasing the level of one or more of glucosylceramide synthase and GM3 synthase in a subject diagnosed with TNBC.
- the method comprises administering an effective amount of Sal-B to the subject.
- ceramide-mediated apoptosis may be induced by decreasing the level of GM3 synthase by administering an effective amount of Sal-B to the subject.
- the levels of GCS and GM3 synthases may be increased alone or in conjunction, at the same level or at different levels, and at the same rate or at different rates in accordance with the present disclosure.
- Sal-B may be administered by any appropriate method, such as intravenous, oral, intraperitoneal, parenteral, intramuscular, intrathecal, subcutaneous, transdermal, vaginal, rectal, sublingual, buccal, nasal, topical, inhalation spray, or any combination thereof.
- Sal-B can be prepared in a variety of forms and may comprise a variety of optional ingredients.
- the formulation may include ingredients such as but not limited to preservatives, lubricant, stabilizer, colorant, diluent, isotonic agent, pH modifier, buffer, excipient, and the like and additional active ingredients, if desired.
- any additional ingredients included in the composition should not negatively impact the stability of the Sal-B and any other active ingredient(s) in the composition.
- a liquid formulation can be prepared, such as, for example, in the form of a solution, emulsion, or suspension in a non-toxic, pharmaceutically-acceptable carrier.
- Exemplary pharmaceutically-acceptable carriers include saline, buffered saline, isotonic saline, Ringer's solution, dextrose, sterile water, deionized water, glycerol, ethanol, 5% dextrose in water, and combinations thereof.
- the drug may be a powder or lyophilisate that is reconstituted with a solvent prior to use.
- the formulation may be in the form of an emulsion or liquid concentrate that is suitable for dilution prior to administration.
- the form of composition is a sterile injectable, which may be aqueous or in a suspension.
- excipients, surfactants, stabilizers, carriers, or a combination thereof may be employed for delivery of the medicament.
- dosage forms may be immediate-release. In other embodiments, dosage forms may be sustained-release.
- the Sal-B or its salt or solvate may be provided in a form including, but not limited to, capsules, tablets, pills, aqueous suspensions, or solutions.
- the active ingredient may be combined with emulsifying and suspending agents. Certain sweetening, flavoring, or coloring agents, or a combination thereof may also be added.
- the method of treatment may include administering at least one additional therapy to the subject.
- the at least one additional therapy may comprise one or more of radiotherapy, surgery, therapeutic agent, hormone ablation therapy, pro-apoptosis therapy, and immunotherapy.
- the additional therapeutic agent may be, for example, chemotherapeutic, antimicrobial, antifungal, antiviral, anti-inflammatory, or a combination thereof.
- the chemotherapeutic agents may be anthracyclines, such as doxorubicin, daunorubicin, and idarubicin; taxanes, such as docetaxel and paclitaxel; pyrimidine antagonists, such as cytarabine, 5-fluorouracil, gemcitabine, and capecitabine; or vinca alkaloids, such as vincristine and vinblastine.
- anthracyclines such as doxorubicin, daunorubicin, and idarubicin
- taxanes such as docetaxel and paclitaxel
- pyrimidine antagonists such as cytarabine, 5-fluorouracil, gemcitabine, and capecitabine
- vinca alkaloids such as vincristine and vinblastine.
- the at least one additional therapy may be administered concurrently with the administration of Sal-B.
- concurrently or “co-administering” and the like refer to the administration of a single composition containing two or more actives, or the administration of each active as separate compositions and/or delivered by separate routes either contemporaneously or simultaneously or sequentially within a short enough period of time that the effective result is equivalent to that obtained when all such actives are administered as a single composition.
- simultaneous is meant that the active agents are administered at substantially the same time, and desirably together in the same formulation.
- the active agents are administered closely in time, e.g., one agent is administered within from about one minute to within about 24 hours before or after another. Any contemporaneous time may be useful. However, it will often be the case that when not administered simultaneously, the agents will be administered within about one minute to within about eight hours and suitably within less than about four hours, in another aspect less than about 1 hour. When administered contemporaneously, the agents are suitably administered at the same site on the subject.
- the term “same site” includes the exact location but can be within about 0.5 to about 15 centimeters, preferably from within about 0.5 to about 5 centimeters.
- the term “separately” as used herein means that the agents are administered at an interval, for example at an interval of about 24 hours to several weeks or months.
- the active agents may be administered in either order.
- the term “sequentially” as used herein means that the agents are administered in sequence, for example at an interval or intervals of minutes, hours, days, or weeks. If appropriate the active agents may be administered in a regular repeating cycle.
- Sal-B may be administered once a day (i.e., a 24-hour period). In other methods, Sal-B may be administered more than once a day. In yet other methods, Sal-B may be administered at least once per week but more infrequently than once a day.
- the administered dose may be about 0.1 ⁇ g/kg ( ⁇ g per kg bodyweight) to about 500 mg/kg, in another aspect about 0.1 ⁇ g/kg to about 100 mg/kg or about 100 ⁇ g/kg to about 1 mg/kg.
- the dose may be about 10 ⁇ g/kg to about 20 ⁇ g/kg, about 20 ⁇ g/kg to about 30 ⁇ g/kg, about 30 ⁇ g/kg to about 40 ⁇ g/kg, about 40 ⁇ g/kg to about 50 ⁇ g/kg, about 50 ⁇ g/kg to about 60 ⁇ g/kg, about 60 ⁇ g/kg to about 70 ⁇ g/kg, about 70 ⁇ g/kg to about 80 ⁇ g/kg, about 80 ⁇ g/kg to about 90 ⁇ g/kg, about 90 ⁇ g/kg to about 100 ⁇ g/kg, about 100 ⁇ g/kg to about 200 ⁇ g/kg, about 200 ⁇ g/kg to about 300 ⁇ g/kg, about 300 ⁇ g/kg to about 400 ⁇
- an optimal dosage may be determined empirically for each subject being treated and may depend upon a variety of factors, including the activity of the agents; the age, body weight, general health, and diet of the individual; the time and route of administration; and other medications the individual is taking. Optimal dosages may be established using routine testing and procedures that are well known in the art.
- Sal-B or a pharmaceutically acceptable salt or solvate thereof is provided for use in the manufacture of a medicament for treating triple negative breast cancer is provided.
- Sal-B is provided for use as a medicament for treating triple negative breast cancer.
- the medicament may be formulated for administration by at least one of intravenous, oral, parenteral, intraperitoneal, intramuscular, intrathecal, subcutaneous, transdermal, vaginal, rectal, sublingual, buccal, nasal, topical, or inhalation spray administration.
- Sal-B is formulated at a dose of about 1 ⁇ g to about 100 mg/kg.
- the pharmaceutically acceptable salt is an aluminum salt, calcium salt, iron salt, magnesium salt, manganese salt, or a combination thereof.
- MDA human triple negative MDA-MB-231
- MCF-7 human estrogen receptor ⁇ positive MCF-7
- MCF-7 and MDA human breast cancer cell lines stably transfected with firefly luciferase gene were purchased from Caliper Life Sciences (Hanover, Md.).
- MCF-7 cells were cultured in DMEM medium (Invitrogen, Carlsbad, Calif.) and MDA cells were grown in DMEM/F-12 (1:1) medium (Invitrogen). Both media were supplemented with 10% fetal bovine serum (Invitrogen) and antibiotic-antimycotic mixture (100 IU/ml penicillin and 100 ⁇ g/ml streptomycin; Cellgro). The cells were maintained at 37° C. in 5% CO2. All experiments were performed when the cells were in the logarithmic phase of growth.
- Sal-B was extracted from Salvia miltiorrhiza Bunge powder with 70% ethanol in a Soxhlet extractor. The extract was then passed through a D101 Macroporous resin and the magnesium salt of Sal-B was eluted with a six-fold column volume of about 20-40% ethanol solutions. The Sal-B magnesium salt-rich fraction in 40% ethanol was concentrated and converted into free Sal-B by adjusting to pH 3-4 with hydrochloric acid. The free Sal-B was dried and dissolved in water and purified with a polyamide chromatographic column. The highly purified Sal-B (>95%) was analyzed with high-pressure liquid chromatography. Before use, the purified Sal-B was dissolved in molecular grade water.
- the monoclonal or polyclonal antibodies against ceramides, survivin, Bcl-xL, caspase-3, caspase-8, cyclin A, cyclin B1, and PCNA were purchased from Sigma (St. Louis, Mo.).
- the anti-ceramide monoclonal antibody (clone: MID 15B4) recognizes free and bound ceramides and its reactivity is species independent.
- the antibodies against ⁇ -actin and p-ERK were obtained from Santa Cruz (Santa Cruz, Calif.).
- the antibodies against GCS and GM3 synthase were obtained from NOVUS (Cambridge, UK) and anti-ER- ⁇ antibody was from Dako (Carpinteria, Calif.).
- Luciferase assay The MDA cell line and the hormone receptor-positive MCF-7 cell line were utilized to test the effectiveness of Sal-B and doxorubicin on cancer cell viability. Both cell lines had been stably transfected and expressed the firefly luciferase gene. The bioluminescent signal intensity reflects the cell metabolic activity, being highly correlated with the cell viability. Cell viability was evaluated using the sensitive bioluminescent optical imaging.
- the cells (10,000 per well) were seeded in flat-bottomed 96-well plates in the above-identified medium with 10% fetal bovine serum and allowed to grow overnight. The old medium was then replaced with fresh medium containing different concentrations of Sal-B (50, 100, 150, and 200 ⁇ M) or doxorubicin (0.1, 0.2, 0.5, and 1 ⁇ M). The cells were further cultured for 24 hours and D-luciferin was added to each well and mixed gently (final concentration of 150 ⁇ /ml). The signal was measured with the Xenogen IVIS 200 imaging system (Caliper Life Sciences, Hopkinton, Mass., USA).
- the system was equipped with a highly sensitive, cooled charge-coupled device (CCD) camera and a light-tight specimen box. Imaging and quantification of signals was controlled by the acquisition and analysis software Living Image 3.0. The bioluminescent signal from the cells in each well was expressed as total flux (photons per second (p/s)). At least five replicates were performed in each experiment, and each experiment was repeated at least three times. The representative data are presented.
- CCD charge-coupled device
- doxorubicin reduced the viability of MCF-7 cells by approximately 67%, whereas there was only 25% reduction for the MDA cells (P ⁇ 0.05). No further reduction of the cell viability was observed in both cell lines treated with 1 ⁇ M doxorubicin. Accordingly, the results demonstrated that Sal-B was able to reduce the cell viability of both MDA and MCF-7 cells in vitro; showing an IC 50 of 125 ⁇ M for MDA cells and 120 ⁇ M for MCF-7 cells. The effect of doxorubicin (1 ⁇ M) on the cell viability was approximately two-fold higher for MCF-7 cells than for MDA cells.
- Colony formation assay The inhibitory effect of Sal-B was further confirmed by colony formation assay.
- the colony formation assay was performed as described previously (Hao Y, et al., “Enforced expression of miR-101 inhibits prostate cancer cell growth by modulating the COX-2 pathway in vivo,” Cancer Prev Res (Phila). 2011; 4: 1073-1083). Briefly, MDA cells were seeded at a density of 300 cells per well in 6-well plates, cultured overnight, and then treated with Sal-B at different concentrations (1, 10, 20, 50, and 100 ⁇ M) for 24 hours. Following treatment, the old medium containing Sal-B was replaced with fresh drug-free media and the cells were allowed to grow for 10 days to permit colony formation from viable clonogenic cells.
- Colonies were stained with 0.1% trypan blue in 50% ethanol and were counted manually under microscopy with a grid printed on a transparent plastic sheet to keep track of colonies counted. The colonies containing more than 50 cells were considered to represent a viable clonogenic cell. The experiment was completed in triplicate for each treatment.
- cyclin A and cyclin B1 Two cell cycle-related proteins—cyclin A and cyclin B1—was checked by Western blot.
- the expression of cyclin A and cyclin B1 was normalized by the expression of the internal control ⁇ -actin (lower panel).
- the cells were treated with 50 ⁇ M and 100 ⁇ M Sal-B, respectively, for 24 hours.
- Doxorubicin (0.1 ⁇ M and 1 ⁇ M) was used as a control.
- down-regulation of cyclin B1 but not cyclin A expression was found in both Sal-B treated MDA and MCF-7 cells.
- Treatment with 1 ⁇ M doxorubicin resulted in reduction of both cyclin A and cyclin B1 expression in both cell lines.
- cyclin B1 is a key component in the control of cell cycle progression from G2 to M phase.
- doxorubicin effectively decreased the expression of both cyclin A and cyclin B1 in both cell lines.
- MDA cells (3 ⁇ 10 6 /50 ⁇ L/spot) were subcutaneously injected into the both sides of lower back of mice using a 27-gauge needle.
- the mice with tumors ( ⁇ 5 mm in diameter) were randomly divided into Sal-B treated, doxorubicin treated, and untreated groups (five mice per group), and were administrated Sal-B (80 mg/kg, three times per week), doxorubicin (4 mg/kg, every four weeks) and 0.9% saline (50 three times per week), respectively, by intraperitoneal injection for a total of 37 days.
- the average tumor weights of Sal-B treated group (0.26 ⁇ 0.06 g) and doxorubicin treated group (0.34 ⁇ 0.09 g) were both significantly smaller than that of untreated control group (0.81 ⁇ 0.12 g) (both P ⁇ 0.05).
- the body weights of mice were measured every week and there were no significant differences between untreated mice and treated mice (data not shown).
- Immunohistochemical staining was performed as described previously (Hao Y, et al., “Enforced expression of miR-101 inhibits prostate cancer cell growth by modulating the COX-2 pathway in vivo,” Cancer Prev Res (Phila), 2011; 4: 1073-1083).
- Deparaffinized specimens were first labeled with anti-PCNA, Bcl-xL, survivin, or ceramide antibody and secondary antibody sequentially. The slides were then stained with streptavidin-horseradish peroxidase and imaged with a microscope equipped with a camera and linked to a computer. For the quantification, ten high-magnification (40 ⁇ ) fields were randomly selected from each slide of tumors and the positive cells were counted. The protein expression was expressed as the average number of positive cells per high magnification field.
- PCNA proliferating cell nuclear antigen
- Apoptotic cells in MDA tumor xenografts were also analyzed by a terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay using the TdT-FragEL DNA Fragmentation Detection Kit (EMD Millipore, Burlington, Mass.) as previously described (Li H, et al., “Cellular uptake and anticancer activity of salvianolic acid B phospholipid complex loaded nanoparticles in head and neck cancer and precancer cells,” Colloids Surf B Biointerfaces. 2016; 147: 65-72).
- TUNEL terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling
- the immunohistochemical results were consistent with those from Western blotting ( FIG. 7 , panel A).
- Western blot analysis was used to determine the expression of apoptosis-related proteins Bcl-xL, survivin, caspase-3 and caspase-8 ( FIG. 7 , panel A).
- ⁇ -actin was used as an internal control for Western blotting.
- the MCD-7 and MDA cells were treated with Sal-B (50 ⁇ M and 100 ⁇ M) and doxorubicin (0.1 ⁇ M and 1 ⁇ M), respectively, for 24 hours. Proteins were extracted from the cells with RIPA lysis buffer (Santa Cruz Biotechnology, Santa Cruz, Calif.) and the protein concentrations were quantified with Bio-Rad protein quantification kit.
- both Sal-B and doxorubicin downregulated both Bcl-xL and survivin protein expression but not the protein levels of caspase-3 and caspase-8 in the MDA and MCF-7 cell lines.
- Sphingolipids such as ceramides
- Sphingolipids play an important biological role in the regulation of proliferation, differentiation, and apoptosis of cancer cells. Intracellular ceramide accumulation has been shown to enhance the apoptosis of cancer cells. Development of drug resistance of cancer cells is also associated with an increase in ceramide glycosylation.
- Glucosylceramide synthase (GCS) is a key enzyme in converting ceramide to glucosylceramide, catalyzing the first reaction of ceramide glycosylation in sphingolipid metabolism.
- GM3 synthase catalyzes the initial step in the biosynthesis of most complex gangliosides from lactosylceramide. Both synthases closely regulate the ceramide metabolism. Early inhibition of GCS has the potential to prevent drug resistance.
- Ceramide levels were further analyzed with flow cytometry, according to the method described above, through comparison of Sal-B treated and untreated MDA cells.
- MDA cells were treated with 50 ⁇ M and 100 ⁇ M of Sal-B, respectively, for 24 hours and ceramide levels were then analyzed by flow cytometry. It was found that 50 ⁇ M of Sal-B was sufficient to enhance the ceramide level ( FIG. 9 , panel A).
- triple-negative breast cancer presents the lack of expression of estrogen receptor ⁇ (ER- ⁇ ), progesterone receptor, and human epidermal growth factor receptor-2 (HER2).
- ER- ⁇ estrogen receptor ⁇
- progesterone receptor progesterone receptor
- HER2 human epidermal growth factor receptor-2
- FIG. 10 panel A shows the ER- ⁇ expression in MCF-7 cells treated with Sal-B and doxorubicin.
- the amount of protein was normalized by that of the internal control ⁇ -actin.
- the results showed that ER- ⁇ protein level was decreased by exposure to doxorubicin at the high dose (1 ⁇ M) but not to Sal-B ( FIG. 10 , panel A).
- the MAPK/ERK pathway is a chain of proteins in the cells, which communicates a signal from a receptor on the surface of cells to the DNA in the nucleus of the cells, critical for establishing solid tumor growth, especially for breast cancer.
- P-ERK is a critical member in MAPK signal pathway and also a marker of the activation of MAPK signal pathway in up-regulating cell proliferation.
- Sal-B significantly decreased the p-ERK expression in both cell lines, suggesting that Sal-B might inhibit cell proliferation of TNBC cells by regulating MAPK signal pathway. Ceramides may interact with the MAPK pathway through inhibiting the p-ERK expression.
- p-ERK extracellular signal-regulated kinases
Abstract
Description
- This application claims the benefit of U.S. Provisional Application No. 62/656,204, filed on Apr. 11, 2018.
- This invention was made in part with U.S. Government support under NIH P20 CA118770. The U.S. Government may have certain rights in this invention.
- This application relates to the treatment of cancer by administering salvianolic acid B, and in particular to the treatment of triple-negative breast cancer.
- Breast cancer is the most common cancer in women and the second highest lethal form of cancer in the United States. Studies have shown that the incidence of breast cancer has been gradually decreasing in the last two decades; however, women in the United States have a one in eight chance of developing breast cancer in their lifetimes.
- About one third of breast cancer is triple-negative breast cancer (“TNBC”), presenting the lack of expression of estrogen receptor α (ER-α), progesterone receptor, and human epidermal growth factor receptor-2 (HER2). Due to the poor response to anti-hormonal treatment and chemotherapeutics, TNBC is considered an aggressive form of breast cancer. The commonly used therapeutic agents for breast cancer, including doxorubicin, have little success in treating patients with TNBC. Doxorubicin also has limited clinical application due to the risk of cardiotoxicity.
- A need exists for an effective treatment of triple-negative breast cancer without the significant side effects of doxorubicin.
- Salvianolic acid B (Sal-B) is a natural compound extracted from Salvia miltiorrhiza Bunge, a well-known Chinese herbal medicine for preventing and treating vascular diseases.
- As described herein, Sal-B has surprisingly been found to have a high potency against triple negative breast cancer (TNBC), which is mediated at least in part by inhibiting tumor cell growth and enhancing ceramide-mediated apoptosis through GCS-catalyzed ceramide glycosylation.
- In one aspect, a method of treating breast cancer in a subject in need thereof is provided. The method comprises administering a therapeutically effective amount of Sal-B to the subject. In one particular approach, the breast cancer is TNBC.
- In accordance with one aspect of the present disclosure, a method for treating cancer in a subject includes inducing ceramide-mediated apoptosis of cancer cells by decreasing the level of one or more of glucosylceramide synthase and GM3 synthase in the subject through the use of an effective amount of Sal-B. In one particular approach, the cancer is TNBC.
- A method of inducing ceramide-mediated apoptosis by decreasing the level of one or more of glucosylceramide synthase and GM3 synthase in cancer cells of a subject is also provided. The method comprises administering to said subject an effective amount of Sal-B.
- Sal-B may be administered by any suitable route, including any of intravenous, oral, parenteral, intraperitoneal, intramuscular, intrathecal, subcutaneous, transdermal, vaginal, rectal, sublingual, buccal, nasal, topical, or inhalation spray. In one aspect, the Sal-B is administered once a day. In another aspect, the Sal-B may be administered at a dose of about 0.1 μg to about 500 mg/kg.
- In any of the embodiments or aspects described herein, Sal-B may be provided in the form of a pharmaceutically acceptable salt or solvate. In one aspect, the pharmaceutically acceptable salt may be an aluminum salt, calcium salt, iron salt, magnesium salt, manganese salt, or combination thereof.
- In yet another approach, the method further includes administering at least one additional therapy to the subject. For example, the at least one additional therapy may comprise one or more of radiotherapy, surgery, chemotherapeutic agent, hormone ablation therapy, pro-apoptosis therapy, and immunotherapy. In one aspect, the chemotherapeutic agent may comprise doxorubicin.
- In yet another approach, Sal-B or a pharmaceutically acceptable salt or solvate thereof is provided for use in the manufacture of a medicament for treating triple negative breast cancer is provided. In another approach, Sal-B or a pharmaceutically acceptable salt or solvate thereof is provided for use as a medicament for treating triple negative breast cancer.
- The medicament may be formulated for administration by at least one of intravenous, oral, parenteral, intraperitoneal, intramuscular, intrathecal, subcutaneous, transdermal, vaginal, rectal, sublingual, buccal, nasal, topical, or inhalation spray administration. In one aspect, the Sal-B is formulated at a dose of about 0.1 μg to about 500 mg/kg. In another aspect, the pharmaceutically acceptable salt is an aluminum salt, calcium salt, iron salt, magnesium salt, manganese salt, or a combination thereof.
- In any of the aspects described herein, the subject may be a mammal, and preferably is a human.
-
FIG. 1 includes luciferase-based bioluminescent images and graphs showing the relative survival percentage of MDA-MB-231 (“MDA”) and MCF-7 cells after exposure to various concentrations of Sal-B and doxorubicin. Inhibitory effects of Sal-B on the cell viability and colony formation of both triple-negative MDA cells and hormone-receptor positive MCF-7 breast cancer cells are demonstrated. The cell viability was analyzed by luciferase-based bioluminescent imaging after exposure to Sal-B (50 μM, 100 μM, 150 μM and 200 μM) (panel A) and doxorubicin (0.1 μM, 0.2 μM, 0.5 μM and 1 μM) (panel B) for 24 hours, respectively. There were significant differences in the cell viability between untreated and Sal-B treated cells (P<0.05). No significant difference was observed for the effect of Sal-B on the cell viability between MDA cells and MCF-7 cells (P>0.05), different from that of doxorubicin (P<0.05). -
FIG. 2 includes photographs and bar graphs showing the colony formation ability of MDA and MCF-7 cells after exposure to various concentrations of Sal-B and doxorubicin. The colony formation of MDA cells was determined with colony formation assay after exposure to various doses of Sal-B (1 μM, 10 μM, 25 μM, 50 μM and 100 μM) for 24 h and colonies were allowed to grow for 10 days. A colony containing more than 50 cells was considered to represent a viable clonogenic cell. The results represent the mean±SD. There were significant differences for the colony formation capability between untreated and Sal-B treated cells (P<0.05). -
FIG. 3 includes flow cytometry plots and bar graphs showing the effects of Sal-B on cell cycle and cell cycle related protein expression in MCF-7 and MDA cells. Panels A and B show the DNA content profiles of MCF-7 and MDA cells, respectively, by flow cytometry. The percentages of cells in the different phases of cell cycle are summarized as mean±SD (panel C). No significant change was observed in the cell cycle phases of either MDA or MCF-7 cells after Sal-B treatment. -
FIG. 4 includes Western blot results for the expression of cell cycle related protein cyclin A and cyclin B1. The expression of cyclin A and cyclin B1 was normalized by the expression of the internal control β-actin. The cells were treated with 50 μM and 100 μM Sal-B, respectively, for 24 hours. Doxorubicin (0.1 μM and 1 μM) was used as a control. For the cyclin A and cyclin B1 expression, down-regulation of cyclin B1 but not cyclin A expression was found in both Sal-B treated MDA and MCF-7 cells. Treatment with 1 μM doxorubicin resulted in reduction of both cyclin A and cyclin B1 expression in both cell lines. -
FIG. 5 is a bar graph showing the inhibitory effects of Sal-B on the growth of triple-negative MDA tumor xenografts in nude mice. The mice were treated with either Sal-B (80 mg/kg three times per week) or doxorubicin (4 mg/kg every 4 weeks) and all mice were sacrificed on day 37. The bar graph shows the tumor weights on day 37. The results represent the mean±SD and *P<0.05 means significant difference with respect to control mice. -
FIG. 6 includes immunohistochemical analysis for proliferating cell nuclear antigen (PCNA) levels in Sal-B treated and doxorubicin treated tumors. The PCNA levels were higher in untreated tumors than in Sal-B treated and doxorubicin treated tumors. -
FIG. 7 includes Western blot and immunohistochemical analysis demonstrating the effects of Sal-B on the apoptosis in both MCF-7 and MDA cancer cells and tumor xenografts. As shown in panel A, Western blot analysis was used to determine the expression of apoptosis-related proteins Bcl-xL, survivin, caspase-3 and caspase-8. β-actin was used as an internal control. The cells were treated with Sal-B (50 μM and 100 μM) and doxorubicin (0.1 μM and 1 μM), respectively, for 24 hours. Both Sal-B and doxorubicin downregulated both Bcl-xL and survivin protein expression, but not the protein levels of caspase-3 and caspase-8 in the MDA and MCF-7 cell lines. Immunohistochemical analysis was used to detect the expressions of Bcl-xL (panel B) and survivin (panel C) in MDA tumor xenografts, showing decreased expression of Bcl-xL and survivin in the Sal-B and doxorubicin treated tumors than in the untreated tumors (P<0.05). Apoptotic cells in MDA tumor xenografts were analyzed by a TUNEL assay, showing an increase in apoptotic cells in the Sal-B and doxorubicin treated xenografts than in the untreated tumors (P<0.05) (panel D). -
FIG. 8 includes Western blot results and bar graphs showing the expression of glucosylceramide synthase (GCS) and GM3 synthase in MDA and MCF-7 cells treated by various concentrations of Sal-B (panel A). The amount of protein expression was normalized by the expression of the internal control β-actin (panels B and C). Results demonstrated that Sal-B enhances ceramide accumulation and decreases the expression of GCS and GM3 enzymes. -
FIG. 9 includes a flow cytometry plot (panel A), bar graph (panel B), and immunohistochemistry images (panel C). MDA cells were treated with 50 μM and 100 μM of Sal-B, respectively, for 24 h and ceramide levels were then analyzed by flow cytometry (A). Immunohistochemistry was used to evaluate the expression of ceramides in MDA tumor xenografts (C) and the ceramide positive cells were counted (B). -
FIG. 10 includes Western blot images and bar graphs showing the effects of Sal-B on the ER-α and p-ERK expression in cancer cells. Panel A shows the ER-α expression in MCF-7 cells treated with Sal-B and doxorubicin and panel B shows the expression of p-ERK in MCF-7 and MDA cells following exposure to different concentrations of Sal-B for 24 hours. The amount of protein was normalized by that of the internal control β-actin. - Salvianolic acid B (Sal-B) is a natural compound extracted from Salvia miltiorrhiza Bunge, a well-known Chinese herbal medicine for preventing and treating vascular diseases. Sal-B has the following structure:
- As described herein, Sal-B has surprisingly been found to have a high potency against triple-negative breast cancer (TNBC), which is mediated at least in part by inhibiting tumor cell growth and enhancing ceramide-mediated apoptosis through GCS-catalyzed ceramide glycosylation. TNBC is considered a very aggressive form of breast cancer and has been challenging to treat due to the poor response to anti-hormonal treatment and chemotherapeutics.
- Described herein are methods of treating cancer in a subject in need thereof comprising administering Sal-B to the subject. In one aspect, the cancer may be treated by inducing ceramide-mediated apoptosis in cancer cells by administering a therapeutically effective amount of Sal-B. In another aspect, the cancer is treated by enhancing, ceramide-mediated apoptosis by decreasing expression of glucosylceramide synthase and/or GM3 synthase. Significantly, early inhibition of GCS has potential to prevent drug resistance. The cancer being treated is one in, which ceramide-mediated apoptosis can be induced via the decrease in expression of one or more of glucosylceramide and GM3 synthase. In one aspect, the cancer being treated is breast cancer, and in a more particular aspect, the cancer being treated is triple-negative breast cancer (TNBC).
- While previous studies have found, that Sal-B has a suppressing effect against head and, neck squamous carcinoma cells via dose-dependent inhibition of prostaglandin E2 synthesis and inhibition of COX-2 expression, it was surprisingly found herein that Sal-B was effective to increase ceramide accumulation and inhibit anti-apoptotic protein expression in TNBC cells. Interestingly, the ceramide accumulation was accompanied by decreased expression of glucosylceramide and GM3 synthases, which are two key enzymes regulating ceramide metabolism. By the present disclosure, it was demonstrated that Sal-B exerts its antitumor effects at least partially by inducing the ceramide accumulation and ceramide-mediated apoptosis via inhibiting the expression of glucosylceramide and GM3 synthases, which was independent of estrogen receptor α.
- As generally used herein, the term “subject” refers to a mammalian subject, in one particular aspect a human subject, in need of a treatment. In one particular aspect, the subject may be any one of a subject having been diagnosed with a cancer (such as TNBC), a subject undergoing treatment for any disorder including a cancer (such as TNBC), an asymptomatic subject having undergone a test or scan indicative of an underlying condition, a symptomatic subject having undergone a test or scan indicative of an underlying condition, a subject undergoing clinical treatment including cancer therapy or clinical intervention in the form of drugs, chemotherapy, immunotherapy, surgery, radiation or therapeutic devices, or not yet undergoing any clinical treatment.
- As used herein, the terms “treatment,” “treating,” and the like refer to an intervention performed to alter the pathology of, or carrying out a procedure, to obtain a desired pharmacologic and/or physiologic effect. The effect may be therapeutic in terms of effecting a partial or complete cure for a disease, condition, symptom, and/or adverse effect attributable to the disease or condition. These terms also cover any treatment of a condition or disease in the subject, and include: (a) inhibiting the disease, i.e., arresting its development; (b) causing regression of the disease; (c) reducing the severity of a symptom of the disease; and/or (d) reducing the frequency of a symptom of the disease or condition.
- The terms “cancer” and “cancerous” refer to or describe the physiological condition in mammals that is typically characterized in part by unregulated cell growth. As used herein, the term “cancer” refers to non-metastatic and metastatic cancers, including early stage and late stage cancers. As noted above, the cancer being treated herein is one in which ceramide-mediated apoptosis can be induced via the decrease in expression of at least one of glucosylceramide synthase and GM3 synthase. In one aspect, the cancer is breast cancer. In another particular aspect, the cancer is TNBC.
- A therapeutically effective amount may be an amount sufficient to provide an observable therapeutic benefit. As used herein, the terms “therapeutically effective amount” or “effective amount” refer to the amount of Sal-B and/or other active ingredient required to confer a biological or meaningful benefit to the subject, such as a biological or medical response or improvement sought by a medical doctor or other medical professional. In one aspect, the terms “therapeutically effective amount” or “effective amount” are intended to mean the amount of Sal-B and/or other active ingredient that will bring about a biologically meaningful improvement in a subject's symptom or prognosis. Doses that exhibit large therapeutic indices are preferred. Effective amounts may vary, as recognized by those skilled in the art, depending, for example, on route of administration, dosage form, inclusion of additional active agents, as well as age, weight, sensitivity, and health of the subject.
- In any of the embodiments described herein, the Sal-B may be in the form of a pharmaceutically acceptance salt or solvate. A pharmaceutically acceptable salt may be any salt which retains the activity of the parent compound and does not impart any unduly undesirable effects on a subject to whom it is administered and in the context in which it is administered. Pharmaceutically acceptable salts may include, but are not limited to, metal salts such as aluminum, calcium, iron, magnesium, manganese, and complex salts.
- In another aspect of the present disclosure, a method is provided for inducing ceramide-mediated apoptosis by decreasing the level of one or more of glucosylceramide synthase and GM3 synthase in a subject diagnosed with TNBC. The method comprises administering an effective amount of Sal-B to the subject. In another aspect of the present disclosure, ceramide-mediated apoptosis may be induced by decreasing the level of GM3 synthase by administering an effective amount of Sal-B to the subject. The levels of GCS and GM3 synthases may be increased alone or in conjunction, at the same level or at different levels, and at the same rate or at different rates in accordance with the present disclosure.
- Sal-B may be administered by any appropriate method, such as intravenous, oral, intraperitoneal, parenteral, intramuscular, intrathecal, subcutaneous, transdermal, vaginal, rectal, sublingual, buccal, nasal, topical, inhalation spray, or any combination thereof.
- Sal-B can be prepared in a variety of forms and may comprise a variety of optional ingredients. For example, the formulation may include ingredients such as but not limited to preservatives, lubricant, stabilizer, colorant, diluent, isotonic agent, pH modifier, buffer, excipient, and the like and additional active ingredients, if desired. In some approaches, any additional ingredients included in the composition should not negatively impact the stability of the Sal-B and any other active ingredient(s) in the composition. For example, a liquid formulation can be prepared, such as, for example, in the form of a solution, emulsion, or suspension in a non-toxic, pharmaceutically-acceptable carrier. Exemplary pharmaceutically-acceptable carriers include saline, buffered saline, isotonic saline, Ringer's solution, dextrose, sterile water, deionized water, glycerol, ethanol, 5% dextrose in water, and combinations thereof. In another aspect, the drug may be a powder or lyophilisate that is reconstituted with a solvent prior to use. In yet another aspect, the formulation may be in the form of an emulsion or liquid concentrate that is suitable for dilution prior to administration. In one aspect, the form of composition is a sterile injectable, which may be aqueous or in a suspension. In some embodiments, excipients, surfactants, stabilizers, carriers, or a combination thereof may be employed for delivery of the medicament. In some embodiments, dosage forms may be immediate-release. In other embodiments, dosage forms may be sustained-release.
- For oral administration, the Sal-B or its salt or solvate may be provided in a form including, but not limited to, capsules, tablets, pills, aqueous suspensions, or solutions. When aqueous suspensions are required for oral use, the active ingredient may be combined with emulsifying and suspending agents. Certain sweetening, flavoring, or coloring agents, or a combination thereof may also be added.
- In some embodiments of the present disclosure, the method of treatment may include administering at least one additional therapy to the subject. The at least one additional therapy may comprise one or more of radiotherapy, surgery, therapeutic agent, hormone ablation therapy, pro-apoptosis therapy, and immunotherapy. The additional therapeutic agent may be, for example, chemotherapeutic, antimicrobial, antifungal, antiviral, anti-inflammatory, or a combination thereof. In some embodiments, the chemotherapeutic agents may be anthracyclines, such as doxorubicin, daunorubicin, and idarubicin; taxanes, such as docetaxel and paclitaxel; pyrimidine antagonists, such as cytarabine, 5-fluorouracil, gemcitabine, and capecitabine; or vinca alkaloids, such as vincristine and vinblastine.
- In one approach, the at least one additional therapy may be administered concurrently with the administration of Sal-B. The term “concurrently” or “co-administering” and the like refer to the administration of a single composition containing two or more actives, or the administration of each active as separate compositions and/or delivered by separate routes either contemporaneously or simultaneously or sequentially within a short enough period of time that the effective result is equivalent to that obtained when all such actives are administered as a single composition. By “simultaneously” is meant that the active agents are administered at substantially the same time, and desirably together in the same formulation. By “contemporaneously” it is meant that the active agents are administered closely in time, e.g., one agent is administered within from about one minute to within about 24 hours before or after another. Any contemporaneous time may be useful. However, it will often be the case that when not administered simultaneously, the agents will be administered within about one minute to within about eight hours and suitably within less than about four hours, in another aspect less than about 1 hour. When administered contemporaneously, the agents are suitably administered at the same site on the subject. The term “same site” includes the exact location but can be within about 0.5 to about 15 centimeters, preferably from within about 0.5 to about 5 centimeters. The term “separately” as used herein means that the agents are administered at an interval, for example at an interval of about 24 hours to several weeks or months. The active agents may be administered in either order. The term “sequentially” as used herein means that the agents are administered in sequence, for example at an interval or intervals of minutes, hours, days, or weeks. If appropriate the active agents may be administered in a regular repeating cycle.
- In one aspect of the present disclosure, Sal-B may be administered once a day (i.e., a 24-hour period). In other methods, Sal-B may be administered more than once a day. In yet other methods, Sal-B may be administered at least once per week but more infrequently than once a day.
- The administered dose may be about 0.1 μg/kg (μg per kg bodyweight) to about 500 mg/kg, in another aspect about 0.1 μg/kg to about 100 mg/kg or about 100 μg/kg to about 1 mg/kg. For example, the dose may be about 10 μg/kg to about 20 μg/kg, about 20 μg/kg to about 30 μg/kg, about 30 μg/kg to about 40 μg/kg, about 40 μg/kg to about 50 μg/kg, about 50 μg/kg to about 60 μg/kg, about 60 μg/kg to about 70 μg/kg, about 70 μg/kg to about 80 μg/kg, about 80 μg/kg to about 90 μg/kg, about 90 μg/kg to about 100 μg/kg, about 100 μg/kg to about 200 μg/kg, about 200 μg/kg to about 300 μg/kg, about 300 μg/kg to about 400 μg/kg, about 400 μg/kg to about 500 μg/kg, about 500 μg/kg to about 1 mg/kg, about 1 mg/kg to about 100 mg/kg, and about 100 mg/kg to about 500 mg/kg. However, an optimal dosage may be determined empirically for each subject being treated and may depend upon a variety of factors, including the activity of the agents; the age, body weight, general health, and diet of the individual; the time and route of administration; and other medications the individual is taking. Optimal dosages may be established using routine testing and procedures that are well known in the art.
- In yet another approach, Sal-B or a pharmaceutically acceptable salt or solvate thereof is provided for use in the manufacture of a medicament for treating triple negative breast cancer is provided. In another approach, Sal-B is provided for use as a medicament for treating triple negative breast cancer. The medicament may be formulated for administration by at least one of intravenous, oral, parenteral, intraperitoneal, intramuscular, intrathecal, subcutaneous, transdermal, vaginal, rectal, sublingual, buccal, nasal, topical, or inhalation spray administration. In one aspect, Sal-B is formulated at a dose of about 1 μg to about 100 mg/kg. In another aspect, the pharmaceutically acceptable salt is an aluminum salt, calcium salt, iron salt, magnesium salt, manganese salt, or a combination thereof.
- Advantages and embodiments of the method and compositions described herein are further illustrated by the following example; however, the particular conditions, processing schemes, compositions, and amounts thereof recited in these examples, as well as other conditions and details, should not be construed to unduly limit this method. All percentages are by weight unless otherwise indicated.
- To assess the effects of Sal-B on cell viability, cell cycle, and apoptosis in cultured triple negative breast cancer (TNBC) cells and tumor xenografts, the human triple negative MDA-MB-231 (hereinafter “MDA”) breast cancer cell line (test group) and the human estrogen receptor α positive MCF-7 (hereinafter “MCF-7”) breast cancer cell line (control group) were compared.
- Cell lines and culture. MCF-7 and MDA human breast cancer cell lines stably transfected with firefly luciferase gene were purchased from Caliper Life Sciences (Hanover, Md.). MCF-7 cells were cultured in DMEM medium (Invitrogen, Carlsbad, Calif.) and MDA cells were grown in DMEM/F-12 (1:1) medium (Invitrogen). Both media were supplemented with 10% fetal bovine serum (Invitrogen) and antibiotic-antimycotic mixture (100 IU/ml penicillin and 100 μg/ml streptomycin; Cellgro). The cells were maintained at 37° C. in 5% CO2. All experiments were performed when the cells were in the logarithmic phase of growth.
- Preparation of Sal-B and Doxorubicin. Doxorubicin was extracted from commercially available Adriamycin solution (Bedford Lab, Bedford, Ohio).
- Sal-B was extracted from Salvia miltiorrhiza Bunge powder with 70% ethanol in a Soxhlet extractor. The extract was then passed through a D101 Macroporous resin and the magnesium salt of Sal-B was eluted with a six-fold column volume of about 20-40% ethanol solutions. The Sal-B magnesium salt-rich fraction in 40% ethanol was concentrated and converted into free Sal-B by adjusting to pH 3-4 with hydrochloric acid. The free Sal-B was dried and dissolved in water and purified with a polyamide chromatographic column. The highly purified Sal-B (>95%) was analyzed with high-pressure liquid chromatography. Before use, the purified Sal-B was dissolved in molecular grade water.
- Statistical analysis. Values represent the means±SD of a minimum of three replicate tests. Data were analyzed by the Duncan test following the ANOVA procedure when multiple comparisons were made. Differences were considered significant when P<0.05.
- Antibodies. The monoclonal or polyclonal antibodies against ceramides, survivin, Bcl-xL, caspase-3, caspase-8, cyclin A, cyclin B1, and PCNA were purchased from Sigma (St. Louis, Mo.). The anti-ceramide monoclonal antibody (clone: MID 15B4) recognizes free and bound ceramides and its reactivity is species independent. The antibodies against β-actin and p-ERK were obtained from Santa Cruz (Santa Cruz, Calif.). The antibodies against GCS and GM3 synthase were obtained from NOVUS (Cambridge, UK) and anti-ER-α antibody was from Dako (Carpinteria, Calif.).
- Luciferase assay. The MDA cell line and the hormone receptor-positive MCF-7 cell line were utilized to test the effectiveness of Sal-B and doxorubicin on cancer cell viability. Both cell lines had been stably transfected and expressed the firefly luciferase gene. The bioluminescent signal intensity reflects the cell metabolic activity, being highly correlated with the cell viability. Cell viability was evaluated using the sensitive bioluminescent optical imaging.
- The cells (10,000 per well) were seeded in flat-bottomed 96-well plates in the above-identified medium with 10% fetal bovine serum and allowed to grow overnight. The old medium was then replaced with fresh medium containing different concentrations of Sal-B (50, 100, 150, and 200 μM) or doxorubicin (0.1, 0.2, 0.5, and 1 μM). The cells were further cultured for 24 hours and D-luciferin was added to each well and mixed gently (final concentration of 150 μ/ml). The signal was measured with the
Xenogen IVIS 200 imaging system (Caliper Life Sciences, Hopkinton, Mass., USA). The system was equipped with a highly sensitive, cooled charge-coupled device (CCD) camera and a light-tight specimen box. Imaging and quantification of signals was controlled by the acquisition and analysis software Living Image 3.0. The bioluminescent signal from the cells in each well was expressed as total flux (photons per second (p/s)). At least five replicates were performed in each experiment, and each experiment was repeated at least three times. The representative data are presented. - Referring to
FIG. 1 , similar inhibitory effects of Sal-B were observed on the cell viability of both MDA and MCF-7 cells in a dose-dependent manner. Compared with untreated cells, MDA and MCF-7 cells decreased their cell viabilities to 69% and 65%, respectively, when treated with Sal-B at 100 μM for 24 hours (FIG. 1 , panel A). The half maximal inhibitory concentrations (IC50) were 125 μM for MDA cells and 120 μM for MCF-7 cells (FIG. 1 , panel C). No significant difference in the inhibitory effect of Sal-B between the two cell lines was observed. At 0.5 μM concentration, doxorubicin reduced the viability of MCF-7 cells by approximately 67%, whereas there was only 25% reduction for the MDA cells (P<0.05). No further reduction of the cell viability was observed in both cell lines treated with 1 μM doxorubicin. Accordingly, the results demonstrated that Sal-B was able to reduce the cell viability of both MDA and MCF-7 cells in vitro; showing an IC50 of 125 μM for MDA cells and 120 μM for MCF-7 cells. The effect of doxorubicin (1 μM) on the cell viability was approximately two-fold higher for MCF-7 cells than for MDA cells. - Colony formation assay. The inhibitory effect of Sal-B was further confirmed by colony formation assay. The colony formation assay was performed as described previously (Hao Y, et al., “Enforced expression of miR-101 inhibits prostate cancer cell growth by modulating the COX-2 pathway in vivo,” Cancer Prev Res (Phila). 2011; 4: 1073-1083). Briefly, MDA cells were seeded at a density of 300 cells per well in 6-well plates, cultured overnight, and then treated with Sal-B at different concentrations (1, 10, 20, 50, and 100 μM) for 24 hours. Following treatment, the old medium containing Sal-B was replaced with fresh drug-free media and the cells were allowed to grow for 10 days to permit colony formation from viable clonogenic cells. Colonies were stained with 0.1% trypan blue in 50% ethanol and were counted manually under microscopy with a grid printed on a transparent plastic sheet to keep track of colonies counted. The colonies containing more than 50 cells were considered to represent a viable clonogenic cell. The experiment was completed in triplicate for each treatment.
- There were significant differences in the cell viability and colony formation capability between untreated and Sal-B treated cells (P<0.05). As shown in
FIG. 2 , the colony formation capability of the cells treated at the concentration of 1 μM was approximately 69% of that of the control cells, and a complete inhibition of the cell colony formation capability was observed at 100 μM. The results represent the mean±SD (FIG. 2 ). These results indicate that Sal-B has an inhibitory effect on TNBC cell growth in vitro. - Cell cycle profile analysis using flow cytometry and Western blot analysis. To understand the effects of Sal-B on the cell cycle of cancer cells, the cell cycle profile was analyzed using flow cytometry. The cells from both cell lines were treated with Sal-B (50 and 100 μM) or doxorubicin (0.1 and 1 μM) for 24 hours and then fixed in chilled 80% ethanol. The fixed cells were incubated in a solution containing 100 μg/mL RNase at 37° C. water bath for 45 minutes. Propidium iodide (final concentration of 50 μg/ml) was then added to the cells and incubated in a 37° C. water bath for another 15 minutes. The analysis was carried out with a FACStar flow cytometer (Becton Dickinson, San Jose, Calif.). Ten thousand cells per sample were analyzed, each sample was done in triplicate and the experiment was repeated three times.
- There were no significant changes in the cell cycle phases for either MDA or MCF-7 cells after exposure for 24 hours to Sal-B at concentrations of 50 μM (
FIG. 3 , panel A andFIG. 3 , panel C) and 100 μM (FIG. 3 , panel B andFIG. 3 , panel C). - The expression of two cell cycle-related proteins—cyclin A and cyclin B1—was checked by Western blot. The expression of cyclin A and cyclin B1 was normalized by the expression of the internal control β-actin (lower panel). The cells were treated with 50 μM and 100 μM Sal-B, respectively, for 24 hours. Doxorubicin (0.1 μM and 1 μM) was used as a control. As shown in
FIG. 4 , down-regulation of cyclin B1 but not cyclin A expression was found in both Sal-B treated MDA and MCF-7 cells. Treatment with 1 μM doxorubicin resulted in reduction of both cyclin A and cyclin B1 expression in both cell lines. The results may be explained by that the cell cycle progression is controlled by a large set of molecules, although cyclin B1 is a key component in the control of cell cycle progression from G2 to M phase. Differently, doxorubicin effectively decreased the expression of both cyclin A and cyclin B1 in both cell lines. - Human tumor xenografts in athymic nude mice. The above findings showed that Sal-B could inhibit the proliferation of MDA cells in vitro, so the effects of Sal-B on the growth of MDA tumor xenografts in animals was then tested. The animal protocol was approved by the Howard University Animal Care and Use Committee. Four-week-old female athymic nude mice (Nu/Nu) were obtained from Harlan Sprague Dawley (Indianapolis, Ind.). All mice were provided the Harlan Teklad #2018 Global 18% protein rodent diet and water ad libitum. Mice were housed in temperature-controlled rooms (74±2° F.) with a 12-hour alternating light-dark cycle. MDA cells (3×106/50 μL/spot) were subcutaneously injected into the both sides of lower back of mice using a 27-gauge needle. On
day 10 after cell implantation, the mice with tumors (˜5 mm in diameter) were randomly divided into Sal-B treated, doxorubicin treated, and untreated groups (five mice per group), and were administrated Sal-B (80 mg/kg, three times per week), doxorubicin (4 mg/kg, every four weeks) and 0.9% saline (50 three times per week), respectively, by intraperitoneal injection for a total of 37 days. (Our previous studies have shown that treatment with Sal-B at 80 mg/kg three times per week leads to no obvious side effects, but a higher dosage has resulted in the weight loss in some mice.) Mouse weight was measured once a week and tumor size was monitored by manual measurement with a caliper. All mice were sacrificed on day 37. - As shown in
FIG. 5 , the average tumor weights of Sal-B treated group (0.26±0.06 g) and doxorubicin treated group (0.34±0.09 g) were both significantly smaller than that of untreated control group (0.81±0.12 g) (both P<0.05). During the experimental period, the body weights of mice were measured every week and there were no significant differences between untreated mice and treated mice (data not shown). - Immunohistochemical Staining and Western Blot Analysis.
- Immunohistochemical staining was performed as described previously (Hao Y, et al., “Enforced expression of miR-101 inhibits prostate cancer cell growth by modulating the COX-2 pathway in vivo,” Cancer Prev Res (Phila), 2011; 4: 1073-1083). Deparaffinized specimens were first labeled with anti-PCNA, Bcl-xL, survivin, or ceramide antibody and secondary antibody sequentially. The slides were then stained with streptavidin-horseradish peroxidase and imaged with a microscope equipped with a camera and linked to a computer. For the quantification, ten high-magnification (40×) fields were randomly selected from each slide of tumors and the positive cells were counted. The protein expression was expressed as the average number of positive cells per high magnification field.
- In parallel with the decreased tumor growth described above, the immunohistochemical analysis demonstrated that proliferating cell nuclear antigen (PCNA) levels were higher in untreated MDA tumor xenografts than in Sal-B treated and doxorubicin treated tumor xenografts (
FIG. 6 ). The results represent the mean±SD and *P<0.05 means significant difference with respect to control mice. - The expression of Bcl-xL decreased significantly in the Sal-B treated tumors (1.3±0.4) than in untreated tumors (11.8±3.0) (P<0.05) (
FIG. 7 , panel B). Survivin level showed similar changes, decreasing in Sal-B and doxorubicin treated groups compared to that in untreated group (FIG. 7 , panel C). - Apoptotic cells in MDA tumor xenografts were also analyzed by a terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay using the TdT-FragEL DNA Fragmentation Detection Kit (EMD Millipore, Burlington, Mass.) as previously described (Li H, et al., “Cellular uptake and anticancer activity of salvianolic acid B phospholipid complex loaded nanoparticles in head and neck cancer and precancer cells,” Colloids Surf B Biointerfaces. 2016; 147: 65-72). Briefly, sections were digested with proteinase K, and endogenous peroxidase activity was blocked with 3% hydrogen peroxide in 10 mM Tris (pH 8.0). The sections were then placed in equilibration buffer and incubated with TdT enzyme in a humid chamber at 37° C. for 1.5 hours. The apoptotic nuclei were stained by 3,3′-diaminobenzidine and observed by microscopy. The number of positively stained nuclei were manually counted and the percentage of positive cells versus the total number of cells was calculated. the highest number of apoptotic cells was found in the Sal-B treated xenografts (12.2±3.2), followed by doxorubicin treated xenografts (9.0±2.1), significantly different from that in the untreated tumors (3.1±1.8) (both P<0.05) (
FIG. 7 , panel D). - The immunohistochemical results were consistent with those from Western blotting (
FIG. 7 , panel A). Western blot analysis was used to determine the expression of apoptosis-related proteins Bcl-xL, survivin, caspase-3 and caspase-8 (FIG. 7 , panel A). β-actin was used as an internal control for Western blotting. The MCD-7 and MDA cells were treated with Sal-B (50 μM and 100 μM) and doxorubicin (0.1 μM and 1 μM), respectively, for 24 hours. Proteins were extracted from the cells with RIPA lysis buffer (Santa Cruz Biotechnology, Santa Cruz, Calif.) and the protein concentrations were quantified with Bio-Rad protein quantification kit. Whole-cell proteins were separated on 8% SDS-polyacrylamide gel, transferred to the polyvinylidene difluoride membrane (Bio-Rad), and then probed with the indicated primary antibodies overnight at 4° C. Washed blots were then incubated with horseradish peroxidase-conjugated anti-rabbit, anti-mouse, or anti-goat antibody (Santa Cruz Biotechnology), respectively, for one hour at room temperature. Blots were developed and visualized with ECL detection system (Bio-Rad). - As shown in
FIG. 7 , panel A, both Sal-B and doxorubicin downregulated both Bcl-xL and survivin protein expression but not the protein levels of caspase-3 and caspase-8 in the MDA and MCF-7 cell lines. - Ceramide Levels
- Sphingolipids, such as ceramides, play an important biological role in the regulation of proliferation, differentiation, and apoptosis of cancer cells. Intracellular ceramide accumulation has been shown to enhance the apoptosis of cancer cells. Development of drug resistance of cancer cells is also associated with an increase in ceramide glycosylation. Glucosylceramide synthase (GCS) is a key enzyme in converting ceramide to glucosylceramide, catalyzing the first reaction of ceramide glycosylation in sphingolipid metabolism. GM3 synthase catalyzes the initial step in the biosynthesis of most complex gangliosides from lactosylceramide. Both synthases closely regulate the ceramide metabolism. Early inhibition of GCS has the potential to prevent drug resistance.
- To understand the mechanism underlying increased ceramide accumulation, the expression levels of GCS and GM3 synthase were measured by Western blot analysis in MDA and MCF-7 cells treated by various concentrations of Sal-B (
FIG. 8 ). The amount of protein expression was normalized by the expression of the internal control β-actin. As shown inFIG. 8 , a low dose (50 μM) of Sal-B was sufficient to inhibit GCS protein level in both MCF-7 and MDA cells. No further inhibitory effect was observed on GCS expression when treated with a higher dose (100 μM). The expression of GM3 synthase was also significantly diminished in the Sal-B-treated MDA cells at both 50 μM and 100 μM, and in the MCF-7 cells at 100 μM. Sal-B was found effective to down-regulate GCS and GM3 synthase expression in cancer cells. - Suppression of GCS and GM3 enzymes by Sal-B may lead to the accumulation of ceramides in cancer cells. As reported by others, doxorubicin has also been shown to induce ceramide accumulation in cancer cells by other studies. Both Sal-B and doxorubicin may induce TNBC cell apoptosis through the ceramide-mediated pathway. Early inhibition of GCS has potential to prevent drug resistance.
- Ceramide levels were further analyzed with flow cytometry, according to the method described above, through comparison of Sal-B treated and untreated MDA cells. MDA cells were treated with 50 μM and 100 μM of Sal-B, respectively, for 24 hours and ceramide levels were then analyzed by flow cytometry. It was found that 50 μM of Sal-B was sufficient to enhance the ceramide level (
FIG. 9 , panel A). - Similarly, immunohistochemistry was carried out, as generally described above, to evaluate the expression of ceramides in MDA tumor xenografts (
FIG. 9 , panel C). The fixed cells were sequentially incubated with anti-ceramide primary antibody (1:100) for 2 hours and PE-labeled secondary antibody (1:200) for 30 minutes, and the ceramide positive cells were counted (FIG. 9 , panel B). Ceramide levels significantly increased in both Sal-B-treated (9.6±2.4) and doxorubicin-treated (6.2±1.3) MDA tumor xenografts, compared to that in untreated control (2.3±0.7) (both P<0.05) (FIG. 9 , panel B). - ER-α and p-ERK Expression.
- As noted above, triple-negative breast cancer presents the lack of expression of estrogen receptor α (ER-α), progesterone receptor, and human epidermal growth factor receptor-2 (HER2). To understand whether Sal-B regulated the expression of ER-α, the ER-α expression in MCF-7 cells was analyzed.
-
FIG. 10 , panel A shows the ER-α expression in MCF-7 cells treated with Sal-B and doxorubicin. The amount of protein was normalized by that of the internal control β-actin. The results showed that ER-α protein level was decreased by exposure to doxorubicin at the high dose (1 μM) but not to Sal-B (FIG. 10 , panel A). - The MAPK/ERK pathway is a chain of proteins in the cells, which communicates a signal from a receptor on the surface of cells to the DNA in the nucleus of the cells, critical for establishing solid tumor growth, especially for breast cancer. P-ERK is a critical member in MAPK signal pathway and also a marker of the activation of MAPK signal pathway in up-regulating cell proliferation. Sal-B significantly decreased the p-ERK expression in both cell lines, suggesting that Sal-B might inhibit cell proliferation of TNBC cells by regulating MAPK signal pathway. Ceramides may interact with the MAPK pathway through inhibiting the p-ERK expression.
- Because phospho-p44/42 extracellular signal-regulated kinases (p-ERK) is a key enzyme in the MAPK signal pathway, the expression of p-ERK was also investigated in MCF-7 and MDA cells following exposure to different concentrations of Sal-B for 24 hours. As shown in
FIG. 10 , panel B, p-ERK was down-regulated by Sal-B in both MCF-7 and MDA cells (FIG. 10 , panel B). - While this disclosure has been particularly described with specific reference to particular processes and embodiments, it will be appreciated that various alterations, modifications, and adaptations may be based on the present disclosure, and are intended to be within the spirit and scope of the disclosure as defined by the following claims.
Claims (21)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/046,577 US20210106552A1 (en) | 2018-04-11 | 2019-04-11 | Methods for treating triple negative breast cancer using salvianolic acid b |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862656204P | 2018-04-11 | 2018-04-11 | |
US17/046,577 US20210106552A1 (en) | 2018-04-11 | 2019-04-11 | Methods for treating triple negative breast cancer using salvianolic acid b |
PCT/US2019/027029 WO2019200131A1 (en) | 2018-04-11 | 2019-04-11 | Methods for treating triple negative breast cancer using salvianolic acid b |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210106552A1 true US20210106552A1 (en) | 2021-04-15 |
Family
ID=68164604
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/046,577 Pending US20210106552A1 (en) | 2018-04-11 | 2019-04-11 | Methods for treating triple negative breast cancer using salvianolic acid b |
Country Status (2)
Country | Link |
---|---|
US (1) | US20210106552A1 (en) |
WO (1) | WO2019200131A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116036070A (en) * | 2022-12-16 | 2023-05-02 | 南京医科大学 | Application of 9' -salvianolic acid B monomethyl ester in preparation of medicines for treating breast cancer tumor cell proliferation, migration and invasion |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20230147718A1 (en) * | 2020-04-09 | 2023-05-11 | Gjmedi | Composition for cancer prevention or treatment, containing, as active ingredient, salvianolic acid b or tanshinone i |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101664400B (en) * | 2002-09-13 | 2012-04-18 | 北京东方天甲科技发展有限公司 | Application of salvianolic acid B to preparation of medicament for treating tumor |
TWI621443B (en) * | 2013-07-11 | 2018-04-21 | Tasly Pharmaceutical Group Co Ltd | Traditional Chinese medicine composition and its use, medicinal preparation containing the traditional Chinese medicine composition and compound salvia miltiorrhiza micro-droplet, and preparation method of the microdroplet |
-
2019
- 2019-04-11 US US17/046,577 patent/US20210106552A1/en active Pending
- 2019-04-11 WO PCT/US2019/027029 patent/WO2019200131A1/en active Application Filing
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116036070A (en) * | 2022-12-16 | 2023-05-02 | 南京医科大学 | Application of 9' -salvianolic acid B monomethyl ester in preparation of medicines for treating breast cancer tumor cell proliferation, migration and invasion |
Also Published As
Publication number | Publication date |
---|---|
WO2019200131A1 (en) | 2019-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11723947B2 (en) | Anti-senescence compounds and uses thereof | |
Guo et al. | GW4064 enhances the chemosensitivity of colorectal cancer to oxaliplatin by inducing pyroptosis | |
Sha et al. | Antitumor properties of Salvianolic acid B against triple-negative and hormone receptor-positive breast cancer cells via ceramide-mediated apoptosis | |
Hong et al. | Wogonin exacerbates the cytotoxic effect of oxaliplatin by inducing nitrosative stress and autophagy in human gastric cancer cells | |
Qian et al. | Pharmacological manipulation of Ezh2 with salvianolic acid B results in tumor vascular normalization and synergizes with cisplatin and T cell-mediated immunotherapy | |
US20210106552A1 (en) | Methods for treating triple negative breast cancer using salvianolic acid b | |
Tang et al. | Regulation of CP-25 on P-glycoprotein in synoviocytes of rats with adjuvant arthritis | |
JP2021505571A (en) | Compositions and Methods for Treating Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma | |
TW201609094A (en) | Novel methods for treating cancer | |
Jiang et al. | Arsenic trioxide cooperate cryptotanshinone exerts antitumor effect by medicating macrophage polarization through glycolysis | |
US9782393B2 (en) | Pharmaceutical compositions and methods for treating cancer and biomarkers for drug screening | |
Li et al. | Harpagoside protects against doxorubicin-induced cardiotoxicity via P53-Parkin-mediated mitophagy | |
Chen et al. | Salvianolic acid B renders glioma cells more sensitive to radiation via Fis-1-mediated mitochondrial dysfunction | |
Chu et al. | Synergistic effects of sodium butyrate and cisplatin against cervical carcinoma in vitro and in vivo | |
Wang et al. | Shikonin alleviates choroidal neovascularization by inhibiting proangiogenic factor production from infiltrating macrophages | |
Bader et al. | Synergistic effects of deuterium oxide and gemcitabine in human pancreatic cancer cell lines | |
US20130177627A1 (en) | Growth inhibitory effects of nanoparticles containing triterpene glycosides or triterpenes | |
US20180133192A1 (en) | Fructose analogs and their combinations as anti-cancer agents | |
IL308668A (en) | Composition for treating autoimmune, alloimmune, inflammatory, and mitochondrial conditions, and uses thereof | |
WO2020230701A1 (en) | Antitumor agent and compounding agent | |
Rotgerink et al. | Experimental Investigation of Lung Toxicity after Radiation Therapy Combined with Immune Checkpoint Inhibitors | |
JP6437649B2 (en) | Pharmaceutical composition for cancer treatment and biomarker for drug screening | |
Lin et al. | Ginsenoside Rb1 induces hepatic stellate cell ferroptosis to alleviate liver fibrosis via the BECN1/SLC7A11 axis | |
Zhang et al. | Dihydroartemisinin suppresses glioma growth by repressing ERRα-mediated mitochondrial biogenesis | |
PEHLİVAN et al. | Is dexmedetomidine toxic on kidney cells (hek-293)? effects on cytotoxicity, reactive oxygen species (ROS) and apoptosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: HOWARD UNIVERSITY, DISTRICT OF COLUMBIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GU, XINBIN;REEL/FRAME:054091/0652 Effective date: 20201016 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCV | Information on status: appeal procedure |
Free format text: NOTICE OF APPEAL FILED |